4-phenylbutyric acid has been researched along with alpha-synuclein in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, DM; Leng, Y | 1 |
| Ariga, H; Inden, M; Kaneko, M; Kitamura, Y; Kobayashi, Y; Okuma, Y; Shimohama, S; Taira, T; Takata, K; Takeuchi, H; Taniguchi, T; Yanagida, T; Yoshimoto, K | 1 |
| Hosokawa, M; Ikeda, M; Ikemoto, M; Kawarabayashi, T; Nakashima, M; Nishinakagawa, T; Ono, K; Shoji, M; Takahashi, M | 1 |
| Fellner, L; Krismer, F; Poewe, W; Stefanova, N; Sturm, E; Wenning, GK | 1 |
| Deng, Y; Liu, C; Liu, W; Ma, Z; Tan, X; Wang, C; Xu, B; Xu, ZF; Yan, DY; Yang, TY | 1 |
| Chaturvedi, S; Gupta, P; Mishra, A; Singh, A; Singh, S; Tiwari, S; Wahajuddin, M | 1 |
6 other study(ies) available for 4-phenylbutyric acid and alpha-synuclein
| Article | Year |
|---|---|
Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
Topics: Acetylation; alpha-Synuclein; Animals; Anticonvulsants; Antimanic Agents; Cells, Cultured; Cerebellum; Cerebral Cortex; Glutamic Acid; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Neuroprotective Agents; Oligonucleotides, Antisense; Phenylbutyrates; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Ubiquitin-Conjugating Enzymes; Valproic Acid | 2006 |
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
Topics: alpha-Synuclein; Animals; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Endoplasmic Reticulum; Humans; Male; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenylbutyrates; Rotenone; Substantia Nigra; Tauopathies | 2007 |
A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Topics: alpha-Synuclein; Animals; Blotting, Western; Brain; Dopamine; Humans; Immunohistochemistry; Mice; Mice, Transgenic; Molecular Chaperones; Mutation; Nerve Degeneration; Neurons; Neuroprotective Agents; Phenylbutyrates | 2009 |
Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy.
Topics: Aging; alpha-Synuclein; Animals; Brain; Disease Models, Animal; Epigenesis, Genetic; Female; Gait Disorders, Neurologic; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple System Atrophy; Myelin Proteolipid Protein; Neuroglia; Neurons; Neuroprotective Agents; Phenylbutyrates; Promoter Regions, Genetic; Protein Deglycase DJ-1 | 2016 |
Effect of the cross-talk between autophagy and endoplasmic reticulum stress on Mn-induced alpha-synuclein oligomerization.
Topics: Adenine; alpha-Synuclein; Animals; Apoptosis; Autophagy; Brain; Butylamines; Chlorides; Endoplasmic Reticulum Stress; Environmental Pollutants; Manganese; Manganese Compounds; Mice, Inbred C57BL; Neurons; Phenylbutyrates; Polymerization; Signal Transduction; Sirolimus | 2018 |
4-Phenylbutyrate Mitigates the Motor Impairment and Dopaminergic Neuronal Death During Parkinson's Disease Pathology via Targeting VDAC1 Mediated Mitochondrial Function and Astrocytes Activation.
Topics: alpha-Synuclein; Animals; Astrocytes; bcl-2-Associated X Protein; Calcium; Caspase 3; Cytochromes; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Histone Deacetylases; Mitochondria; Motor Disorders; Neuroprotective Agents; Nitrites; Parkinson Disease; Phenylbutyrates; Protein Aggregates; Rats; Tyrosine 3-Monooxygenase; Voltage-Dependent Anion Channel 1 | 2022 |